KWM
CRSP icon

Kassira Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Kassira Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$864K Buy
15,839
+50
+0.3% +$2.63K 0.69% 38
2026
Q1 		$751K Buy
15,789
+601
+4% +$31.7K 0.69% 37
2025
Q4 		$796K Sell
15,188
-557
-4% -$33.4K 0.76% 36
2025
Q3 		$1.02M Buy
+15,745
New +$904K 0.98% 36

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kassira Wealth Management's CRSP Position: Q2 2026 in Review

Kassira Wealth Management increased its CRISPR Therapeutics (CRSP) stake by 0.32% in Q2 2026, buying an estimated $2.63K and bringing the position to 15,839 shares worth $864K. The position accounts for 0.69% of the portfolio, ranked #38.

Kassira Wealth Management first reported a position in CRSP in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.02M in Q3 2025. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Kassira Wealth Management held 15,839 shares of CRISPR Therapeutics worth $864K as of Q2 2026.
  • Kassira Wealth Management bought 50 CRISPR Therapeutics shares in Q2 2026, an estimated $2.63K.
  • CRISPR Therapeutics made up 0.69% of Kassira Wealth Management's portfolio in Q2 2026, its #38 holding.
  • Kassira Wealth Management first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Kassira Wealth Management's CRISPR Therapeutics position peaked at $1.02M in Q3 2025.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Kassira Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.